Cellrox Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Cellrox's estimated annual revenue is currently $1.3M per year.(i)
  • Cellrox's estimated revenue per employee is $87,000

Employee Data

  • Cellrox has 15 Employees.(i)
  • Cellrox grew their employee count by 7% last year.

Cellrox's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$57.6M31824%N/AN/A
#2
$44.6M28623%$25.4MN/A
#3
$5.1M44-6%N/AN/A
#4
$35.1M225-3%$46.9MN/A
#5
$14.5M1005%N/AN/A
#6
$1.3M15-6%N/AN/A
#7
$1.5M170%N/AN/A
#8
$2.9M29-12%N/AN/A
#9
$125.2M6916%N/AN/A
#10
$95.9M529-1%N/AN/A
Add Company

What Is Cellrox?

Cellrox's Thinvisor is a lightweight mobile virtualization platform that enables multiple Virtual Mobile Instances to coexist on a single device. Each Virtual Mobile Instance is completely isolated, can be customized and transferred to other devices. The Thinvisor ensures that the Virtual Mobile Instances are independent and isolated from one another. Thinvisor maintains device performance, power usage, and support for native applications while providing an intuitive user experience.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$1.3M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cellrox News

2022-04-17 - Mobile Virtualization Market Size And Forecast | Citrix ...

... Harman International Industries Inc, AT&T Inc, Cellrox Pvt Ltd, Blackberry Limited, Oracle Corporation, Microsoft Corporation.

2022-04-13 - Nanosecond-pulsed DBD plasma treatment on human ...

Plasma treated or untreated cells were collected and stained with CellROX Green Reagent (ThermoFisher Scientific, UK) at a concentration of...

2022-04-06 - Liraglutide preserves CD34+ stem cells from dysfunction ...

Immediately after adhesion, cells were incubated with Green CellROX (Life Technologies) for 20 min and then fixed with 2% paraformaldehyde...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M1515%$200M
#2
$0.6M150%$4.3M
#3
$1.1M157%N/A
#4
$1.3M15N/AN/A
#5
$1.3M15N/AN/A